Agoracom Blog
«
»

AGORACOM Welcomes Valeo Pharma $VPH.ca $VPHIF With 7 Products To Be Launched In 2021 / 2022 ($45M. Estimated Peak Sales / Year) $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 3:31 PM on Tuesday, December 15th, 2020

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Commercial Portfolio

VPH-Commercial-Portfolio

Here’s just a few products already approved:

BRAND: REDESCA® (BIOSIMILAR)

Launch: Q1-2021

Status: Approved by Health Canada December 2020

Indication: Injectable blood thinner

Market size:  $200M

Peak sales estimate $30 – $40M, sales margin 55 – 60% https://www.youtube.com/embed/XNn29Cx2ToY

BRAND: HESPERCOTM

Launch: Launched in Q4 -2020

Status: Approved by Health Canada

What is it: Anti-Oxidant – Immune system support

How’s it sold: Retail, Online (www.hesperco.com, www.amazon.ca)

Market Size: $500M

hesperco

BRAND: ONSTRYV®

Launch: Q3 2019

Status: Received positive recommendation for public reimbursement in Quebec

Use: Parkinson’s disease, 1st treatment launched in Canada since 2006

Patient base: 100,000 in Canada 2nd chronic neurodegenerative disorder after Alzheimer

Market Size: $20M

%Peak sales estimate $8M, sales margin 65-70 %

Pipeline

Pipeline

The Valeo Model

Company Forecast

  • All portfolio & pipeline products to be on the market by end 2022
  • Solid pipeline composed of “licensed” products
  • Peak Sales reached 2-4 years after market launch
  • From 1 product on the market to 12 in 4 years and more to come
  • Forecast excludes any new product licensing

Hub On AGORACOM / Corporate Profile

Tags: , , , , , , , , , , , ,

This entry was posted on Tuesday, December 15th, 2020 at 3:31 pm and is filed under AGORACOM Clients (New), All Recent Posts, Featured, Valeo Pharma Inc. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.